tiprankstipranks
NVAX Earnings: Novavax Stock Down on Weak 2024 Revenue Outlook
Market News

NVAX Earnings: Novavax Stock Down on Weak 2024 Revenue Outlook

Story Highlights

Novavax reported better-than-expected Q3 results. However, the stock dropped more than 6% yesterday due to a weak full-year revenue outlook.

Shares of Novavax (NVAX), a pharmaceutical company, declined over 6% following the release of its third-quarter results. Though the company reported a lower-than-expected loss and surpassed revenue estimates, it lowered its full-year revenue guidance, which hurt investor sentiment.

Don't Miss our Black Friday Offers:

For the quarter, Novavax reported a net loss of $0.76 per share, an improvement from the $1.26 loss in the same period last year and better than analysts’ average estimate of a $0.79 loss per share.

Moreover, NVAX reported $84.5 million in revenue, which beat the analysts’ expectations of $73.8 million. However, the top line fell 55% from the year-ago quarter.

Declining COVID-19 Vaccine Sales Hurt Outlook

Novavax lowered its full-year revenue guidance to $650 million-$700 million, down from the previous forecast of $700 million to $800 million. Product sales are now expected between $175 million and $225 million, down from prior guidance of $275 million to $375 million.

The lower outlook is primarily due to declining demand for Novavax’s COVID-19 vaccine, which currently holds a modest 2-3% market share. It faces stiff competition from mRNA vaccines developed by Pfizer (PFE) and Moderna (MRNA).

NVAX Provides Clinical Trial Update

On a positive note, NVAX recently said that the U.S. Food and Drug Administration (FDA) has lifted the hold on one of the company’s clinical trials. This trial involved a new combination of COVID-19 and influenza vaccines. The hold was imposed after a case of motor neuropathy in a participant. Motor neuropathy can cause weakness in the hands and arms, hindering patients from performing daily tasks. With the hold now lifted, Novavax can proceed to Phase 3 trials for these vaccine candidates.

In another positive update, Novavax received authorization from the FDA and European Commission for its updated COVID-19 vaccine for the 2024-25 season, for individuals aged 12 and older.

Is Novavax a Good Stock to Buy?

Turning to Wall Street, NVAX has a Moderate Buy consensus rating based on three Buys, two Holds, and one Sell assigned in the last three months. At $17, the average Novavax price target implies a 100.95% upside potential. Shares of the company have gained 76.25% year-to-date.

See more NVAX analyst ratings

Disclosure

Related Articles
TheFlyLeerink views Chris Boshoff as ‘strong choice’ for Pfizer’s CSO
TheFlyU.K.’s CAT fines Pfizer, Flynn GBP 69M for excessive pricing after CMA probe
Joel BaglolePfizer (PFE) Appoints Company Insider Chris Boshoff as New Head of R&D
Go Ad-Free with Our App